BioPharmSignal logoBioPharmSignal

Biotech News

Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Arbutus (ABUS)ArbutusEarnings

Strong financial position with cash, cash equivalents and marketable securities of $93.7M Moderna litigation U.S. trial scheduled for March 2026; Favorable claim construction ruling in Pfizer-BioNTech litigation issued in September 2025 Additional analysis of imdusiran (AB-729) clinical

Related news

ABUSArbutus2026-05-13 11:30 EST

Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update

ABUSArbutus2026-03-23 11:30 EST

Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update

BRNSBarinthus Biotherapeutics2026-08-06 12:00 EST

Barinthus Bio Reports Second Quarter 2026 Financial Results and Updates on Corporate Developments

BNTXBioNTech2026-08-04 10:45 EST

BioNTech Announces Second Quarter 2026 Financial Results and Corporate Update

BNTXBioNTech2026-07-21 10:45 EST

BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026

SCYXSCYNEXIS2026-05-11 20:23 EST

SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update

BRNSBarinthus Biotherapeutics2026-04-30 11:30 EST

Barinthus Bio Reports First Quarter 2026 Financial Results and Updates on Corporate Developments

AVIRAtea2026-08-05 11:00 EST

Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026

SPROSpero Therapeutics2026-08-04 21:01 EST

Spero Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026

IMNNImunon2026-08-04 12:00 EST

IMUNON to Hold Second Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, August 11, 2026

View all latest news

Arbutus

Hepatitis B Therapeutics Company Arbutus Biopharma develops combination therapies intended to achieve a functional cure for chronic hepatitis B. Imdusiran Imdusiran is an RNA interference therapeutic that reduces production of hepatitis B viral proteins, including surface antigen, and is being studied in combination regimens. Combination...

Recent company news

ABUSArbutus2026-07-16 11:30 EST

Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders

ABUSArbutus2026-05-13 11:30 EST

Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update

ABUSArbutus2026-04-15 11:30 EST

Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B

ABUSArbutus2026-03-23 11:30 EST

Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update

ABUSArbutus2026-03-03 21:15 EST

Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna

Stock data

Close
4.54 USD
Market cap
841.51M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States